James Davis, PharmD, BCOP

332 posts

James Davis, PharmD, BCOP

James Davis, PharmD, BCOP

@thisisJamesD

Malignant hematology pharmacist and affiliate assistant professor @MUSCHollings #lymphoma #myeloma opinions are my own

Charleston, SC Entrou em Mayıs 2021
209 Seguindo609 Seguidores
James Davis, PharmD, BCOP retweetou
Andrew Portuguese, MD
Andrew Portuguese, MD@AJPortuguese·
Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. ashpublications.org/bloodneoplasia…
Rahul Banerjee, MD, FACP@RahulBanerjeeMD

Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time. "Can I get MMR 💉 on dara-len maintenance?" Short answer: 💯%, it seems! Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!

English
0
4
14
1.6K
James Davis, PharmD, BCOP retweetou
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time. "Can I get MMR 💉 on dara-len maintenance?" Short answer: 💯%, it seems! Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
Rahul Banerjee, MD, FACP tweet media
English
3
8
35
4.1K
Gareth Morgan
Gareth Morgan@DrGarethMorgan1·
This figure from my friend Peter Vorhees has to be the most complicated and weirdly beautiful I’ve ever seen
Gareth Morgan tweet media
English
4
7
31
2.3K
James Davis, PharmD, BCOP
James Davis, PharmD, BCOP@thisisJamesD·
Earlier in the year we published efficacy of #pocketdex in patients receiving teclistamab, Sunday we present our group’s second pharmD led oral abstract at #ASH25 validating the safety of dex with talquetmab. Again, you don’t need toci for low grade CRS! doi.org/10.1182/blood-…
James Davis, PharmD, BCOP tweet media
English
0
7
32
1.8K
James Davis, PharmD, BCOP retweetou
Robert Z. Orlowski
Robert Z. Orlowski@Myeloma_Doc·
#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): pubmed.ncbi.nlm.nih.gov/41221958/. #mmsm
Robert Z. Orlowski tweet mediaRobert Z. Orlowski tweet mediaRobert Z. Orlowski tweet mediaRobert Z. Orlowski tweet media
English
1
14
32
3.6K
James Davis, PharmD, BCOP retweetou
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
10/ #ASH25 Abstract 720: 1st-line CRS Tx with dex in #MMsm bsAbs (McElwee @thisisJamesD et al) "Pocket dex": equal efficacy, way cheaper / simpler than toci, albeit >1 dose more likely. This makes outpt bsAb SUD *way* easier for pts. As I now say: #Downwithdex #ExceptforCRS !
Rahul Banerjee, MD, FACP tweet media
English
2
3
11
1.1K
James Davis, PharmD, BCOP retweetou
Rahul Banerjee, MD, FACP
Rahul Banerjee, MD, FACP@RahulBanerjeeMD·
1/ Thanks Larry (and all co-authors) and @AjHematology for this! RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"... Can we predict delayed response conversion?
Rahul Banerjee, MD, FACP tweet media
Larry Anderson,MD,PhD,FACP@ldandersonjr

Great job leading this one @RahulBanerjeeMD D30 ALC is a significant predictor of delayed responses to Tec in RRMM for initial non-responders. American Journal of Hematology | onlinelibrary.wiley.com/doi/10.1002/aj… @GKaurMD @AlGarfall @SurbhiSidanaMD @utswcancer #USMyelomaImmunotherapyConsortium

English
3
13
53
6.4K
James Davis, PharmD, BCOP retweetou
Karen Sweiss
Karen Sweiss@KarenSweiss·
Excited to share our newesr manuscript! Great collab w/ US Myeloma Immunotherapy Consortium showing impact of Flu LD exposure on CAR-T outcomes! Need prospective studies to validate model but even more 👀 on personalized chemo dosing! astctjournal.org/article/S2666-…
English
0
9
14
2.3K

Descobrir

@BloodPortfolio @RahulBanerjeeMD @Bethfaiman @DrGarethMorgan1 @MoffittNews @PennCardiology @PennCancer @md_addison